Limor brings over 15 years of expertise in the biotech industry, with a strong background in R&D, business development, and regulatory affairs. His career encompasses significant roles in both large and small biotech firms.
Prior to joining NurExone, Limor served as a Senior Regulatory Consultant at ADRES Int’l Biotech and Consulting, where he provided strategic guidance to Advanced Therapies companies both in Israel and internationally. At Vaxil Biotherapeutics, a clinical-stage company focused on an innovative cancer vaccine, he was the VP of Operations and Clinical Affairs, overseeing research, regulatory submissions to FDA and EMA, and manufacturing of clinical material for human studies.
Limor also led the Business Development at BiondVax Pharmaceuticals (now Scinai Immunotherapeutics), driving regulatory and business strategies for a major Phase II influenza study and supporting the company’s IPO on the NYSE. He began his career as a Group Leader in Teva’s Special Projects Unit, where he developed products under the 505(b)(2) pathway.
Limor holds a PhD from the Weizmann Institute of Science in Israel, specializing in Immunology and Biophysics, and completed postdoctoral fellowships at MD Anderson Cancer Center in Houston, TX and at the Sunnybrook Research Institute, in Toronto, focusing on translational cancer therapeutics.
